Research Signal – Source date 2022-03-10
Cancer immunotherapy can alter immune activity, raising a serious question during COVID-19: could treatment shortly before infection make the illness more dangerous? In a systematic review and meta-analysis of 20 studies, researchers found no statistically significant association between recent immunotherapy and higher odds of death or severe or critical COVID-19. The result speaks to a specific treatment window and a group-level comparison; it does not establish that every regimen is safe for every patient.
The comparison covered treatment in the month before diagnosis
The review included 6,042 people with cancer who were diagnosed with COVID-19. Of these, 464 had received active immunotherapy within 30 days before their COVID-19 diagnosis. The comparison group consisted of patients who had not received immunotherapy in that window, though the studies did not define the comparison group uniformly.
The authors searched electronic databases; the review was published on March 10, 2022. Five of the included studies were prospective cohort studies, which follow groups forward, and 15 were retrospective, using information already collected. The analysis combined results from both kinds of studies rather than assigning patients to receive or skip treatment.
The pooled numbers show no clear increase
For mortality, the pooled unadjusted odds ratio was 0.92, with a 95% confidence interval from 0.68 to 1.25. An odds ratio compares the odds of an outcome between groups: 1 would indicate equal odds, while values above or below 1 indicate higher or lower odds in the treated group. Here, the interval includes 1, and the result was not statistically significant. The analysis therefore did not detect higher mortality among patients treated within 30 days.
For severe or critical COVID-19, the unadjusted odds ratio was 1.07, with a 95% confidence interval from 0.78 to 1.47. This estimate also was not statistically significant, and its interval includes both lower and higher odds. Severe or critical disease was defined using World Health Organization guidance, though the review notes that definitions varied among studies.
These odds ratios describe comparisons across study groups, not the chance that a particular person will die or become severely ill. They also do not show that immunotherapy lowered either outcome. The result is narrower: the pooled data did not identify a statistically significant increase for these outcomes in the specified treatment window.
Two possible immune effects motivated the question
During infection, the immune system’s inflammatory response can contribute to tissue injury. The authors describe concern that COVID-19 could trigger an excessive inflammatory reaction, making an immune-altering cancer treatment seem like a possible added risk. That was a biological concern motivating the research, not an outcome the meta-analysis measured directly.
The authors also considered another possibility. They cited a study reporting fewer T cells and signs of T-cell exhaustion in people with COVID-19. These immune cells help recognize threats; exhaustion means they are less active. Some cancer immunotherapies can increase T-cell activity, which the authors suggested might counter that exhaustion. Their meta-analysis did not test this mechanism or show that treatment improved COVID-19 outcomes.
Consistency checks do not remove differences between studies
The researchers used a random-effects model to combine odds ratios, giving weight to each study while allowing its underlying effect to differ from others. They also checked whether the pooled results changed when they removed one study at a time. The leave-one-out checks did not significantly alter the estimates, and measured between-study heterogeneity was low for the reported mortality and severe-disease analyses. In other words, no single study appeared to drive the pooled result, and the estimates were statistically consistent across studies.
Those checks address consistency, not whether the groups were comparable in the first place. Fifteen studies compared immunotherapy recipients with people receiving no active anticancer treatment; five compared them with people not receiving active immunotherapy. The authors’ sensitivity analysis found that excluding the latter five studies did not significantly change the pooled results, but the differing comparisons still matter when interpreting what treatment itself may have contributed.
Most studies were retrospective, and patients’ health, cancer type, treatment choices, and COVID-19 circumstances could differ in ways that affect outcomes. The review could not adjust the severe or critical disease analysis for confounding factors because adjusted estimates were unavailable. Variable definitions of severe disease add another source of uncertainty. For mortality, an adjusted pooled estimate was 0.51, with a 95% confidence interval from 0.25 to 1.01 and a P value of 0.053. Although the estimate was below 1, its interval reached 1 and the result was borderline; it is not evidence that immunotherapy protected patients from death.
How this could shape the future
Imagine a future infectious outbreak in which an oncology patient and clinician have dependable comparative evidence to help weigh a planned immunotherapy treatment against infection-related risks. Individualized decisions already existed; stronger evidence could make those decisions better informed. This review contributes a narrower finding about treatment in the 30 days before COVID-19 diagnosis. It does not answer whether continuing, pausing, or starting immunotherapy after diagnosis improves outcomes.
A meaningful next step would be a sufficiently large prospective comparison with clearly defined control groups and adjusted estimates for both mortality and severe disease. If that evidence supports the present finding, it could help clinicians discuss treatment timing with a clearer picture of infection-related risks, while accounting for each patient’s circumstances.
Key Sources
- Primary source: Association of active immunotherapy with outcomes in cancer patients with COVID-19: a systematic review and meta-analysis.
DOI or Journal Page · Review or Meta-Analysis · 2022-03-10
Keep exploring